Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
NCT ID NCT07743164
First seen Aug 03, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This trial is testing whether a new drug called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer and delay cancer growth compared to standard chemotherapy. The study includes adults with high-grade serous or endometrioid ovarian, peritoneal, or fallopian tube cancer that has returned after initial platinum-based treatment and PARP inhibitor maintenance. R-DXd is an antibody-drug conjugate designed to target cancer cells and deliver a toxic agent directly to them. The trial will compare progression-free survival and overall survival between the treatment groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- raludotatug deruxtecan (R-DXd), an antibody-drug conjugate that targets cancer cells and delivers a toxic payload, given alone or with bevacizumab
- What this could lead to
- If successful, this could provide a new, more effective treatment option for people with advanced ovarian cancer that has returned after initial therapy, potentially extending the time before the cancer progresses and improving overall survival.
- What could go wrong
- This is a phase 3 trial, but the drug is still experimental. It may not prove more effective than standard chemotherapy, and it could have side effects, including potential toxicity from the antibody-drug conjugate. Results will take time and may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HIGH-GRADE ENDOMETRIOID EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?